New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsComparePNC-27 vs Melanotan II

PNC-27 vs Melanotan II

Side-by-side comparison of key properties, dosing, and research.

Immune Support
PNC-27
Sexual Health & Libido
Melanotan II
Summary
PNC-27 is a synthetic peptide derived from the p53 tumor suppressor protein, containing both an HDM2-binding domain and a transmembrane penetratin sequence. It selectively kills cancer cells by binding MDM2/HDM2 overexpressed on the plasma membrane of malignant cells, inducing membranolysis without harming normal cells.
Melanotan II is a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH) that stimulates melanin production (skin tanning), suppresses appetite, and enhances sexual function. It is not FDA-approved and has significant safety concerns including mole changes and cardiovascular effects.
Half-Life
Not well established; estimated minutes to hours
1–2 hours
Admin Route
Intravenous (research), Intraperitoneal (research)
SubQ
Research
Typical Dose
Not established for humans; research doses vary by cell line and model
0.25–0.5 mg
Frequency
Not established for human use
Once daily
Key Benefits
  • Selective cytotoxicity against cancer cells overexpressing HDM2/MDM2
  • Spares normal cells lacking surface HDM2 expression
  • Membranolytic mechanism bypasses intracellular resistance pathways
  • Demonstrated activity against breast, pancreatic, leukemia, and melanoma cell lines
  • Potential for combination with conventional chemotherapy
  • Novel non-genotoxic anticancer mechanism
  • Promotes skin tanning and melanin production
  • Reduces UV exposure needed to tan
  • Enhances libido and sexual function
  • May suppress appetite
  • Faster, deeper tan development
  • Longer-lasting tan maintenance
  • Potential photoprotective effects
Side Effects
  • Limited human clinical data; largely in vitro and animal studies
  • Potential immunogenic reactions (foreign peptide)
  • Systemic toxicity at high doses not well characterized
  • Unknown interactions with current chemotherapy agents
  • Nausea (very common, especially in first days)
  • Facial flushing
  • Spontaneous erections in men
  • Darkening or changes in existing moles (monitor closely)
  • +3 more
Stacks With